Abstract
The immune cells within the tumor microenvironment (TME) play important roles in tumorigenesis. The immune evasion capability, as a new hallmark of cancer, provides opportunities for new strategies of cancer therapy, namely harnessing the immune cells to battle the cancer cells. Within the TME, regulatory T cells (Tregs) are one attractive cell type for targeting as they play a critical role in immunosuppression in TME. Therapeutic strategies that specifically inhibit tumor-infiltrating Tregs while sparing peripheral and normal tissue Tregs are highly desirable.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
